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ABSTRACT
Outsourcing is increasingly used by the vaccine manufacturers. When the manufacturing activities are outsourced, 
the contract manufacturer’s Good Manufacturing Practice compliance needs to be confirmed through auditing. In 
the same way, when distribution is outsourced, the contract distributor’s Good Distribution Practice compliance 
needs to be confirmed through auditing. The objective of this study was to develop an audit preparation tool for 
the pharmaceutical contract vaccine distributor and to validate its contents by using the Delphi method. Based on 
this, a tool was developed for the contract vaccine distributors. The Delphi method was used with a group of 14 
experts from the pharmaceutical industry, authorities and university. The response rate in the Delphi questionnaire 
round was 100 %. The tool consisted of 33 quality items, out of which 29 (88%) achieved the pre-defined 
agreement rate level (>75%). The four quality items which did not achieve the pre-defined agreement rate were 
excluded from the tool. The expert group suggested only minor changes to the tool. The results show that the 
content validity of the developed audit preparation tool was good. The resultant questionnaire is ready to use. 
Developed the ready-to-use questionnaire based on critical factors evaluation, gives an objective picture of the 
possibilities of the potential partner and help organisations make quality decision on the selection of contract 
vaccine distributors. The contract vaccine distributor must be permanently controlled and analysed, so as to 
maintain the required quality and to keep low level of costs.
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INTRODUCTION
Reliance on vaccine safety is of  critical 
importance for the national immunisation 
strategies and for the global public health.4 
In order for a safe and secure medicinal 
product to reach the end-user, distribution 
process plays an important role in the qual-
ity maintenance chain, complying with the 
Good Distribution Practice (GDP) guide-
lines5. Taking over the responsibilities for 
maintaining top quality of  a medicine/
product starting from production, through 
distribution, storage, dispensing or sales, to 
the end-user, is a professional obligation 
and ethical responsibility of  all healthcare 
professionals in the medicinal products sup-
ply chain.5 The quality of  medicinal product 
should remain identical until the end-user 
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in accordance with the relevant marketing 
authorisation (MA). The concept of  qual-
ity management and QMS requirements in 
a distribution chain should be in accordance 
with the GMP guidelines.5 Socially account-
able companies in the pharmaceutical sup-
ply chain are faced with the fact of  having 
to establish a growing number of  standards 
which are a necessary condition for doing 
business and market survival.6 The quality 
system (QS) of  pharmaceutical wholesalers 
should ensure that only medicinal products 
with the MA are distributed, that medici-
nal products storage conditions are under 
constant supervision, that the possibility of  
medicinal products contamination or cross 
contamination is minimized during trans-
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port, that the medicinal products are adequately handled 
in the store, and that all medicinal products are kept in 
a proper, safe place. The quality system, among other 
things, should also meet the requirement that the right 
product is delivered to the right address within a satis-
factory period of  time. Monitoring medicines through 
distribution channels should ensure easy detection of  
defective products, and recall procedure should be effi-
cient and quick.7 In comparison with the vaccine pro-
duction costs, the distribution chain investments are 
marginal, but absolutely critical if  we want to see the 
benefit from vaccines.8 Researchers showed that very few 
people have a bird’s eye view of  various health systems 
components and interactions between programmes and 
can comment competently on issues, such as distortion 
of  priorities and opportunity costs.9 This fact emphasize 
the need of  standardize comprehensive procedures.
The pharmaceutical industry is confronted with constant 
challenges. On one side there is legislation requiring the 
production of  quality, efficient and safe medicinal prod-
ucts, and on the other, great pressure to reduce the price 
of  medicinal products, thus imposing the demand for 
costs reduction on pharmaceutical companies.10
Taking these facts into account, the companies focus 
on the development of  their core activities, while the 
non-core activities are outsourced to contractors.11 Out-
sourcing activities also carries a greater risk with regard 
to quality maintenance and regulatory compliance, (e.g.) 
the outsourced contractor must observe company values 
and have strong and short lines of  communication with 
the company. Since these requirements imply a high level 
of  association between the partners, the company should 
have a rationally small number of  outsourced contractors 
with whom strategic partnership has been established.
The specificities of  business operations in the phar-
maceutical field require a multidisciplinary and careful 
approach on one side, and quick and comprehensive solu-
tions on the other. Therefore, the process of  choosing 
an external contractor is based on empirical and, as far as 
possible, adequate criteria for business partner selection. 
Bearing in mind the previously stated pre-conditions, as 
well as the responsibility towards patients` health which 
rests with the Marketing Authorisation holder, the phar-
maceutical company must establish a quality system for 
selecting and monitoring external contractors.
The first step is choosing a method to perform qualifi-
cation of  the potential external contractor.7 The method 
must be simple and reliable. Simplicity will be achieved 
by selecting the appropriate form, while reliability will 
be reached if  tests are included referring to the critical 
points obtained from the risk analysis of  the process for 
which the partner is outsourced. Based on the research 
results, data will be obtained on the weak points of  the 
potential external contractor. Acceptance criteria can be 
based on the number of  weak points found or on the 
specific weaknesses. If  it is determined that the poten-
tial partner meets the pre-defined key aspects, i.e. their 
number, the selection process can continue.
Vaccines are a heterogeneous class of  medicinal prod-
ucts requiring handling in cold chain regime. Therefore, 
WHO issued a series of  guide books aimed at provid-
ing all participants in vaccines storage and distribution 
with clear guidelines and answers, thus reducing the risk 
of  cold chain disruption? Cold chain maintenance in all 
stages of  vaccines handling ensures preserving their sta-
bility during the stipulated shelf-life. As a part of  a wider 
picture, this issue is included in the six Building blocks 
that are considered as a set of  inputs that contribute 
to the desired outcomes of  a health system, improved 
health and health equity, responsiveness, social and 
financial risk protection and improved efficiency, 
through improving access, coverage, quality and safety.12
The aim of  this study was to develop a tool for the prep-
aration of  pharmaceutical contract vaccine manufacturer 
audit. The tool was a questionnaire, with mainly GDP-
related questions, developed based on the questionnaire 
used by WHO for the certification of  companies as the 
National Vaccine Store.13 Unlike the integral WHO ques-
tionnaire, which is lengthy in line with its goal, the ques-
tionnaire resulting from this work is a practical tool for 
the public and private sector organizations without any 
ambitions with regard to WHO certifications. The guid-
ing idea was to make a questionnaire that is easily appli-
cable and reliable. Audit is carried out as a part of  the 
contract distributor selection process,14 so the purpose 
of  the questionnaire was to obtain preliminary informa-
tion about the contract vaccine distributor and help pre-
pare for the audit. Since papers on this topic are very few, 
there is a free room for research in this field which puts 
this work in the rank of  few research papers dealing with 
this important link in the cold chain. The content valid-
ity of  the preparation tool was assured by the Delphi 
method. Guiding idea for the initial selection of  ques-
tions was choosing the questions regarding critical con-
fidence limits of  the distributor’s system performance. 
The selection of  the first round questions covers critical 




Since usage of  the chosen solution provides informa-
tion on weaknesses in the solution, and since the level 
of  experience i.e. the quality of  the solution rises with 
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the passage of  time,15 time for reaching a quality solu-
tion was imposed as the key factor in this research.
As a result, a method was chosen which in a short 
period of  time implements the accumulated experience 
by including experts for the specific field of  research. 
The Delphi method was used in this study. The Delphi 
method is used for making a group judgement on a topic 
for which no or unconvincing research-based informa-
tion exists. In the conventional Delphi method, a small 
expert group develops a questionnaire, which is then 
sent to a larger expert group. The questionnaire is modi-
fied based on the first results and then re-sent together 
with the results from the previous round. The research 
is continued until the consensus has been achieved.16
Step 1: Development of the audit preparation tool
The audit preparation tool was developed together with 
experts (n=4 + researcher) of  the company holding 
the National Vaccine Store certificate issued by WHO 
and UNICEF for storage and distribution of  the case 
company’s vaccines (Figure 1). The case company is a 
medium-sized biotechnological company engaged in 
the production, storage and distribution of  vaccines, 
which has contract with other vaccine manufacturers 
for storage and distribution of  vaccines. The tool was 
developed for the contract storage and distribution of  
vaccines. The experts were trained in the course of  the 
certification preparations, followed by the continuing 
post-certification training. The experts have an exten-
sive experience in auditing vaccines storage and distribu-
tion conditions. This experience was used for choosing 
the questions that could have a key role in drafting the 
potential partner’s capabilities.
Step 2: Delphi questionnaire round
The content validity of  the audit preparation tool was 
assessed using the Delphi method. An expert group10 
was recruited to evaluate the tool contents. The expert 
group consisted of  14 people with extensive experience 
of  pharmaceutical industry and GDP issues. The group 
had members from the case company, other pharma-
ceutical companies, from authorities and from the uni-
versity. The original expert group (n=5) was included in 
this Delphi questionnaire round.
Each respondent was personally contacted before send-
ing the questionnaire, and the purpose of  the Delphi 
questionnaire was explained to them. The questionnaire 
had clear instructions how the respondents should fill it 
in. Anonymity of  the participants was ensured, the ques-
tionnaires were submitted to each respondent individu-
ally, and the responses were processed anonymously17. 
The developed audit preparation tool was sent to 
the respondents in July 2013. The expert group was 
Figure 1: Development of the audit preparation tool7
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requested to evaluate the importance of  each quality 
item in the tool on a 5-point Likert scale ranging from 1 
(strongly disagree) to 5 (totally agree). The expert group 
was also suggested to add questions to the question-
naire and record other comments or ideas relating to 
the content of  the tool. The consensus criterion is the 
number of  responses for one option > 75% out of  the 
total number of  responses for that option. Such quality 
item was interpreted as essential and was kept in the tool. 
Otherwise, the quality item could be interpreted as not 
essential and was excluded from the tool. Similar defini-
tions of  consensus have been provided in the literature.18
RESULTS
Step 1
The original questionnaire consisted of  33 quality items 
in total from 8 different topics: Receipt, Storage, Cold 
room capacity, Buildings, Equipment and vehicles, 
Maintenance of  buildings, Equipment and vehicles, 
Vaccine stock records, Efficacy of  vaccine deliveries to 
the next levels in the distribution system, Written pro-
cedures (Appendix 1). The first part of  the tool con-
tained general information, such as information on the 
manufacturing site and contact person. The 7 remaining 
topics with their contents are presented in Appendix 1 
.15-23 All questions in the tool were close-ended requir-
ing from the respondent to circle one out of  five given 
answers. The consensus on 8 questions was reached in 
the first round.
Step 2
The final version of  the audit preparation tool was 
produced in December 2013 from two Delphi rounds. 
The Delphi questionnaire was sent to 14 experts, all of  
whom returned the completed questionnaire (response 
rate 100%). In the second round, the results from the 
first round were revealed for the questions that did not 
reach consensus. The questions that reached consensus 
in the first round were excluded from the questionnaire 
in the second round. Based on such obtained informa-
tion, the expert group gave answers to the questions 
from the questionnaire for the second round. The level 
of  agreement of  the quality items varied from 57% to 
87% (Appendix 2). After the second round, 4 out of  33 
quality items (12%) did not meet the pre-defined criteria 
for agreement rate (>75%). 
DISCUSSION
The first audit phase of  pharmaceutical distributor’s 
external contractor24,25 is based on the principle of  cre-
ating a preliminary credentials file of  the potential con-
tractor. It includes points relevant in the experts opinion 
for the initial evaluation of  the organization’s capabil-
ity to respond to the imposed requirements in view of  
distribution and storage in the pharmaceutical industry. 
The expert group very quickly reached consensus on 
the questions to be used. Namely, the requested agree-
ment > 75% was achieved already in the second round 
for 29 out of  33 questions.
The expert group reached agreement on all questions in 
the field: receipt, stock records, further deliveries and writ-
ten procedures. However, in the fields of  vaccines storage, 
cold room capacity, infrastructure and maintenance, there 
were questions for which consensus was not reached. 
These questions were excluded from the final tool, and 
the experts did not manage to agree on the answers due to 
different opinions on relevance and purpose of  the ques-
tions. For example, opinions differed as to whether it is 
required to calculate the cold room capacity and whether 
cold room performance test is required to be performed 
twice a year. In view of  these dilemmas, it is good to 
exclude such questions in this phase so as to reduce the 
possibility of  confusion. In the second phase i.e. on-site 
audit, however, answers to questions for which consensus 
was not reached would be sought so as to better estimate 
the level of  business efficiency and degree of  agreement 
with the principles of  prevention and reliability.
Since it is necessary to control the key elements as 
extensively as possible on one side, and on the other 
side resources such as time and money are limited, the 
expert group followed these guidelines in their work.
The fields from which the questions were chosen are 
the key aspects with high values of  estimated risk to the 
process in case of  their non-fulfilment. By pinpointing 
these questions, the risk of  unwanted situations, which 
could potentially occur, is cumulatively reduced. Regard-
less of  the quality of  evaluation methods, a continuous 
and good partner communication could even be a more 
important factor for achieving the set goals.18
CONCLUSION
It is to be expected that a questionnaire conceived in 
such a manner, based on critical factors evaluation, gives 
an objective picture of  the possibilities of  the poten-
tial partner in the fields which are very important for 
an effective and efficient system functioning but which 
require longer preparatory operations and greater 
engagement of  the related resources. If  the pharmaceu-
tical distributor is able to meet the critical minimum in 
the tested domain, it can be claimed with certainty that it 
will also meet other required domains. The contract dis-
tributor must be permanently controlled and analysed,26 
so as to maintain the required quality and to keep low 
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level of  costs. The organizations that have outsourced 
distribution activities are satisfied with the resulting 
effects.27 Authors will continue with activities related to 
contract vaccine distributor’s assessments by conduct-
ing survey based on validated questionnaire. Further 
manuscripts are to be expected.
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APPENDIX 1
PHARMACEUTICAL QUALITY SYSTEM COMPLIANCE ASSESMENT QUESTIONNAIRE 
OF THE VACCINE CONTRACT DISTRIBUTOR




Tel: ____________________ Web mail: ______________________________
Main activity ___________________________________________________
Person who completed the Questionnaire (name, surname, signature, function): ____________________
Qualifications of the responsible person for distribution ________________________________________
Total number of employees: _________
GDP implementation date: ______________No._____________________ (please submit a copy)
Other certificates: ISO 9001, ISO 14 001, ISO 27 000, OHSAS 18 000,_________ (please submit a copy)
Note:
Responses were graded according to the Likert scale (1-5), having also weighting factors (0-19%, etc.) 
/ the same as RADAR methodology. The response is an objective grade given to the question asked, 
by circling one of the five points. 
Response grading: 
1 – not true at all / 2 – partly true / 3 – true / 4 – more than true / 5 – absolutely true
Question Answer (circle)
I Vaccine arrival
Are there pre-shipment and arrival procedures in place? 1    2    3   4   5
Is a satisfactory contingency plan in place in case: 1) flights are 
delayed; 2) the airport cold room has failed or 3) transport to the 
store is delayed?
1    2    3   4   5
Are cold rooms adjusted for vaccine storage (large enough to 
accommodate the largest anticipated vaccine shipment, have a 
secure lock, have a continuous temperature recording device) ?
1    2    3   4   5
Have staff received training in vaccine storage and 
transport? 1    2    3   4   5
Is every vaccine arrival recorded?
II Vaccine storage
Do the employees that handle the vaccines know the correct storage 
temperature range for each of the vaccines? 1    2    3   4   5
Do the employees that handle the vaccines know which vaccines 
will freeze at temperatures below 0°C? 1    2    3   4   5
Is there a complete set of manual temperature records for each and 
every cold room? 1    2    3   4   5
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Is there a tested contingency plan in the event of equipment failure? 1    2    3   4   5
Is the plan rehearsed at least once a year? 1    2    3   4   5
III Cold storage capacity
Has the volume calculation been carried out for all vaccines stored? 1    2    3   4   5
Have capacities of all cold rooms been calculated? 1    2    3   4   5
IV Buildings, equipment and vehicles
Is there a separate packing area close to the cold rooms and the 
needed packing material? 1    2    3   4   5
Is there sufficient space to store packed cold boxes in, or close to 
the packing area and can the temperature of the packing area be 
maintained between 15°C and 25°C throughout the year?
1    2    3   4   5
Do the refrigerated vehicles have an up-to-date service record and 
are the vehicles fitted with continuous temperature recorders? 1    2    3   4   5
Are all cold rooms fitted with adequate shelving and alarm systems? 1    2    3   4   5
Have workers received training in safe working in cold rooms 1    2    3   4   5
Is there an adopted refrigeration equipment replacement plan in 
place? 1    2    3   4   5
V Building, equipment and vehicle maintenance
Are there building, equipment and vehicle maintenance plans? 1    2    3   4   5
Are there records of building, equipment and vehicle maintenance? 1    2    3   4   5
Is there an adopted preventive maintenance plan in place? 1    2    3   4   5
Are there records of preventive maintenance plan realization? 1    2    3   4   5
Are there any procedures for handling in case of equipment failure? 1    2    3   4   5
Are in-house cold room performance checks carried out twice a year 
in extreme temperature conditions? 1    2    3   4   5
VI Stock records
Are records about the type, number (in doses), manufacturer, batch/
lot number, expiry date of the freeze-dried vaccine and diluent 
individually maintained?
1    2    3   4   5
Do stock records indicate adherence to EEFO principles (earliest 
expiry, first out)? 1    2    3   4   5
Are damaged/expired vaccines clearly identified in the stock 
recording system? 1    2    3   4   5
Are stock records data backed up as per the determined dynamics? 1    2    3   4   5
VII Effectiveness of vaccine deliveries to the next level of distribution
Did the primary store send a programme (announce delivery) to the 
intermediate store setting out dates for the delivery and/or collection 
of vaccines?
1    2    3   4   5
Is the reliability of actual delivery/collection dates against the 
programme between 90% and 100%? 1    2    3   4   5
VIII Procedures
Are all processes described in Standard Operating Procedures 
(SOP) and are they observed? 1    2    3   4   5
Are regular internal audits carried out? 1    2    3   4   5
Is the corrective and preventive actions system implemented for the 
observed non-conformities? 1    2    3   4   5
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APPENDIX 2
Indicators of expert group members` agreement on the answers (% of agreement, n=14)
Question                                                                                                                                    Agreement rate
I Vaccine arrival
Are there pre-shipment and arrival procedures in place?                                                                                  86
Is a satisfactory contingency plan in place in case:
1) flights are delayed; 2) the airport cold room has failed or 3) transport to the store is delayed?                      79
Are cold rooms adjusted for vaccine storage 
(large enough to accommodate the largest anticipated vaccine shipment, have a secure lock, 
have a continuous temperature recording device) ?                                                                                         79
Have staff received training in vaccine storage and transport?                                                                         77
Is every vaccine arrival recorded?                                                                                                                     93
II Vaccine storage
Do the employees that handle the vaccines know the correct storage temperature range 
for each of the vaccines?                                                                                                                                   86
Do the employees that handle the vaccines know which vaccines 
will freeze at temperatures below 0°C?                                                                                                              57*
Is there a complete set of manual temperature records for each and every cold room?                                   86
Is there a tested contingency plan in the event of equipment failure?                                                               79
Is the plan rehearsed at least once a year?                                                                                                       83
III Cold storage capacity
Has the volume calculation been carried out for all vaccines stored?                                                               79
Have capacities of all cold rooms been calculated?                                                                                         57*
IV Buildings, equipment and vehicles
Is there a separate packing area close to the cold rooms and the
 needed packing material?                                                                                                                                 79
Is there sufficient space to store packed cold boxes in, or close to 
the packing area 
and can the temperature of the packing area be maintained 
between 15°C and 25°C throughout the year?                                                                                                  86
Do the refrigerated vehicles have an up-to-date service record 
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and are the vehicles fitted 
with continuous temperature recorders?                                                                                                            86
Are all cold rooms fitted with adequate shelving and alarm systems?                                                              75*
Have workers received training in safe working in cold rooms?                                                                       86
Is there an adopted refrigeration equipment replacement plan in place?                                                         86
V Building, equipment and vehicle maintenance
Are there building, equipment and vehicle maintenance plans?                                                                       79
Are there records of building, equipment and vehicle maintenance?                                                               79
Is there an adopted preventive maintenance plan in place?                                                                             86
Are there records of preventive maintenance plan realization?                                                                        86
Are there any procedures for handling in case of equipment failure?                                                               86
Are in-house cold room performance checks carried out twice a year 
in extreme temperature conditions?                                                                                                                  57*
VI Stock records
Are records about the type, number (in doses), manufacturer, batch/lot number, 
expiry date of the freeze-dried vaccine and diluent individually maintained?                                                    93
Do stock records indicate adherence to EEFO principles (earliest expiry, first out)?                                        86
Are damaged/expired vaccines clearly identified in the stock recording system?                                             79
Are stock records data backed up as per the determined dynamics?                                                               86
VII Effectiveness of vaccine deliveries to the next level of distribution
Did the primary store send a programme (announce delivery) to the intermediate 
store setting out dates for the delivery and/or collection of vaccines?                                                               86
Is the reliability of actual delivery/collection dates against the programme 
between 90% and 100%?                                                                                                                                  87
VIII Procedures
Are all processes described in Standard Operating Procedures (SOP) 
and are they observed?                                                                                                                                     79
Are regular internal audits carried out?                                                                                                               86
Is the corrective and preventive actions system implemented 
for the observed non-conformities?                                                                                                                   86
* Agreement rate below the pre-defined criteria excluded the question from the questionnaire.
